CANTA.ST实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 23:29):

Stats
今日成交量	264 059
平均成交量	568 839
市值	576.11M
EPS	SEK0 ( 2024-02-21 )
下一个收益日期	( SEK0 ) 2024-05-21
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.550
ATR14	SEK0.0200 (0.58%)

音量相关性

長: -0.08 (neutral)

短: -0.94 (very strong negative)

Signal:(55.214) Neutral

Cantargia AB (publ) 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Cantargia AB (publ) 相关性 - 货币/商品

-0.37
( neutral )

-0.49
( neutral )

0.00
( neutral )

-0.44
( neutral )

0.00
( neutral )

0.80
( moderate )

Cantargia AB (publ) 财务报表

Annual	2023
营收:	SEK0
毛利润:	SEK-3.45M (0.00 %)
EPS:	SEK-1.650

FY	2023
营收:	SEK0
毛利润:	SEK-3.45M (0.00 %)
EPS:	SEK-1.650

FY	2022
营收:	SEK0
毛利润:	SEK-3.69M (0.00 %)
EPS:	SEK-2.83

FY	2021
营收:	SEK0.00
毛利润:	SEK0.00 (0.00 %)
EPS:	SEK-3.05

Financial Reports:

No articles found.

Cantargia AB (publ)

Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.